These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 24925809

  • 1. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
    de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C, LIFE Study Team.
    Clin Lung Cancer; 2014 Sep; 15(5):338-45.e1. PubMed ID: 24925809
    [Abstract] [Full Text] [Related]

  • 2. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.
    J Clin Oncol; 2011 Nov 01; 29(31):4113-20. PubMed ID: 21969500
    [Abstract] [Full Text] [Related]

  • 3. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
    Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A, LIFE study team.
    J Cancer Res Clin Oncol; 2014 Oct 01; 140(10):1783-93. PubMed ID: 24903964
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 01; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.
    Clin Lung Cancer; 2014 Jan 01; 15(1):86-92. PubMed ID: 24139827
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S, TAILOR trialists.
    Lancet Oncol; 2013 Sep 01; 14(10):981-8. PubMed ID: 23883922
    [Abstract] [Full Text] [Related]

  • 8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.
    J Thorac Oncol; 2008 Dec 01; 3(12):1446-53. PubMed ID: 19057271
    [Abstract] [Full Text] [Related]

  • 10. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M, Swiss Group for Clinical Cancer Research (SAKK).
    Lung Cancer; 2012 Dec 01; 78(3):239-44. PubMed ID: 23009726
    [Abstract] [Full Text] [Related]

  • 11. Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
    Toffalorio F, de Marinis F, Conforti F, Spitaleri G, Catania C, Noberasco C, Lazzari C, Vecchio F, Stufano V, Barberis M, De Pas T.
    J Thorac Oncol; 2015 Feb 01; 10(2):392-6. PubMed ID: 25611230
    [Abstract] [Full Text] [Related]

  • 12. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr 01; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 13. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.
    Hum Pathol; 2014 Dec 01; 45(12):2379-87. PubMed ID: 25288236
    [Abstract] [Full Text] [Related]

  • 14. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 15. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.
    Cancer Genet; 2013 Feb 01; 206(1-2):26-31. PubMed ID: 23313110
    [Abstract] [Full Text] [Related]

  • 16. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F.
    Tumori; 2011 Feb 01; 97(2):160-5. PubMed ID: 21617709
    [Abstract] [Full Text] [Related]

  • 17. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.
    Clin Lung Cancer; 2014 May 01; 15(3):173-81. PubMed ID: 24486058
    [Abstract] [Full Text] [Related]

  • 18. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH.
    J Clin Oncol; 2008 Mar 20; 26(9):1472-8. PubMed ID: 18349398
    [Abstract] [Full Text] [Related]

  • 19. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.
    J Thorac Oncol; 2012 Jan 20; 7(1):98-104. PubMed ID: 22124476
    [Abstract] [Full Text] [Related]

  • 20. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF.
    Clin Cancer Res; 2010 Jun 01; 16(11):3078-87. PubMed ID: 20395213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.